Clinical trials: Venous Thrombosis Upper Extremity
Cardiac Surgery, Central Venous Catheter Thrombosis
Continuous Heparin Infusion to Prevent Catheter-related Thrombosis
Catheter-related thrombosis could impair blood flow in the vein, block the central venous catheter, induce catheter-related infection or venous thromboembolism in the deep veins or pulmonary vessels, which furthermore progress…
- Conditions
- Cardiac Surgery, Central Venous Catheter Thrombosis, Heparin
- Trial name
- NCT04767113
- Testing
- Heparin sodium, Normal saline
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Guangdong Provincial People's Hospital
Venous Thromboembolism, Venous Thromboses
inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT
After hip or knee replacement all patients receive a standardized treatment with blood thinners, this medication is called thrombosis prophylaxis.
- Conditions
- Venous Thromboembolism, Venous Thromboses, Pulmonary Embolism, Deep Vein Thrombosis
- Trial name
- DISTINCT (NCT06581965)
- Testing
- Short duration prophylaxis, Higher intensity and longer duration prophylaxis, Control
- Where
- 13 sites in Netherlands
- Volunteers
- 10,078 people
- Sponsor
- Leiden University Medical Center
Retinal Vein Occlusion
Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion
The purpose of this study is to provide efficacy and safety data of 3 consecutive monthly intravitreal injections with 0.5 mg ranibizumab in Japanese patients with visual impairment due to macular edema secondary to retinal vein…
- Trial name
- RVO in Japan (NCT01377597)
- Testing
- ranibizumab
- Where
- 8 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Central Venous Catheter Thrombosis, Central Venous Catheter Related Bloodstream Infection
CLiCK in the Critical Care Unit
Insertion of a central venous access device (CVAD) allows clinicians to easily access the circulation of a patient to administer life-saving interventions.
- Conditions
- Central Venous Catheter Thrombosis, Central Venous Catheter Related Bloodstream Infection, Catheter Complications, Catheter Blockage
- Trial name
- CLiCK (NCT04548713)
- Testing
- 4% EDTA, Saline
- Where
- 6 sites in Canada
- Volunteers
- 1,449 people
- Sponsor
- Fraser Health
Embolism and Thrombosis
The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis
The purpose of this study is to obtain an estimate of catheter survival in the setting of upper extremity deep vein thrombosis (UEDVT) in patients treated with dalteparin and warfarin.
- Trial name
- NCT00216866
- Testing
- Dalteparin, Warfarin
- Where
- 6 sites in Canada
- Volunteers
- 70 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Pulmonary Embolism, Venous Thromboembolic Disease
Prospective, Multi-center, Single-arm Study to Assess the Safety of Retrieval of the Recovery G2 Filter.
This study was designed to assess the safety of retrieval of the Bard Recovery® G2® Filter System. The G2 filter is an FDA-cleared device for inferior vena caval interruption in patients with pulmonary thromboembolism.
- Trial name
- EVEREST (NCT00556426)
- Testing
- Bard Recovery G2 Filter System
- Volunteers
- 100 people
- Sponsor
- C. R. Bard
Macular Edema, Retinal Vein Occlusion
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
- Trial name
- BEACON (NCT04592419)
- Testing
- KSI-301, Aflibercept
- Where
- 141 sites in United States, Czechia and 10 more
- Volunteers
- 568 people
- Sponsor
- Kodiak Sciences Inc
Acute Deep Venous Thrombosis of Femoral Vein (Disorder)
Preservation of Venous Valvular Function After PMT for Acute DVT
To evaluate the venous valvular function after pharmacomechanical thrombectomy (PMT) for acute femoral-popliteal venous thrombosis.
- Trial name
- PREFER (NCT05588284)
- Testing
- AngioJet device, anticoagulation alone
- Where
- 7 sites in China
- Volunteers
- 100 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Deep Vein Thrombosis
SCD Use to Prevent Deep Venous Thrombosis (DVT) in Patients With PICC Lines
The purpose of this study is to see if a compression device on the arm where a peripherally inserted central catheter (PICC) line has been inserted can prevent the formation of a blood clot around the PICC line.
- Trial name
- NCT01670188
- Testing
- Pneumatic SCD - VenaFlow System (DJO Global)
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Mayo Clinic
DVT - Deep Vein Thrombosis
A Prospective, Multicenter, Single-Arm Trial of Peripheral Vein Thrombectomy Stent System in Deep Venous Thrombosis
To evaluate the safety and efficacy of peripheral vein thrombectomy stent system produced by Shanghai Tendfu Medical Technology Co., Ltd. in the treatment of acute or subacute deep venous thrombosis.
- Trial name
- NCT07857850
- Testing
- Peripheral Vein Thrombectomy Stent System
- Where
- 6 sites in China
- Volunteers
- 132 people
- Sponsor
- Shanghai TENDFO Medical Technology Co., Ltd.
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
This single-center, prospective, single-arm Phase II clinical trial is designed to evaluate the efficacy and safety of combining hepatic artery infusion chemotherapy (HAIC, for up to 4 cycles) with iparomlimab/tuvonralimab plus…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Oligometastases, Radiotherapy
- Trial name
- NCT07062055
- Testing
- Anti-VEGF, Immunotherapy, Local Therapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shandong Cancer Hospital and Institute
Venous Thrombosis
Peripherally Inserted Versus Centrally Inserted Central Venous Catheters in the Neurological Intensive Care
The investigators aim to compare the complications between centrally and peripherally inserted central venous catheters in neurological intensive care unit patients.
- Trial name
- PICNIC (NCT01495429)
- Testing
- Central venous catheter
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of Michigan
Nephrostomy; Complications, Fistula
HoloStream Study - Video Capture Device Usage
Objectives: Primary Evaluate the primary operator usability of VSI streaming software for realtime streaming of images from video capture devices to a head mounted display (Hololens 2) during Interventional Radiology procedures…
- Conditions
- Nephrostomy; Complications, Fistula, Central Venous Catheter Thrombosis
- Trial name
- Holo-Stream (NCT04774588)
- Testing
- VSI streamer and Microsoft Hololens 2 classed as a Class III device by Health Canada.
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Central Venous Catheter Thrombosis
Thrombotic Complications After Central Venous Catheterization
Rationale: Complications related to central venous catheterization are mechanical, infectious or thrombotic in origin. Potential complications of catheter-related thrombosis are not insubstantial and include pulmonary embolism…
- Trial name
- TARZAN (NCT04302376)
- Testing
- Cather-related thrombosis ultrasonography
- Where
- Netherlands
- Volunteers
- 173 people
- Sponsor
- Amsterdam UMC, location VUmc
Hematoma Postoperative, Venous Thromboembolism
Use of Tranexamic Acid in Reduction Mammoplasty
Breast reduction mammoplasty (BRM) is among the most commonly performed procedures in plastic surgery. However, postoperative hematoma is one of the most common complications following BRM.
- Trial name
- TREX-ARM (NCT04947514)
- Testing
- Tranexamic acid
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Central Venous Catheter Thrombosis, Renal Dialysis
The Effectiveness and Safety of 4% Sodium Citrate as a Lock Solution in Central Venous Hemodialysis Catheter
Studies that used a dilute citrate formulation (4%) demonstrated efficacy as an anticoagulant with minimal to no risk of bleeding in HD sessions. This study will compare effectiveness and safety utilizing 4% sodium citrate vs.
- Trial name
- NCT05188339
- Testing
- 4% sodium citrate, heparin group
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Chang Gung Memorial Hospital
Sickle Cell Disease, Central Venous Catheter Thrombosis
THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)
Research Question: In adult SCD patients with CVC, is it feasible and safe to conduct an adequately powered RCT to evaluate the use of rivaroxaban as thromboprophylaxis in this population? Study Design: The study is a vanguard…
- Conditions
- Sickle Cell Disease, Central Venous Catheter Thrombosis, Venous Thromboembolism
- Trial name
- THIS (NCT05033314)
- Testing
- Rivaroxaban 10 MG
- Where
- 3 sites in Canada
- Volunteers
- 4 people
- Sponsor
- University Health Network, Toronto
Deep Vein Thrombosis
Safety and Efficacy Study of OmniWave Endovascular System to Treat Deep Vein Thrombosis
This is a prospective, multi-center single arm registry to assess the use of the OmniWave Endovascular System in subjects presenting with either lower or upper extremity acute (symptoms have been present for greater than or equal…
- Trial name
- SONIC I (NCT00640731)
- Testing
- OmniWave Endovascular System
- Volunteers
- 50 people
- Sponsor
- OmniSonics Medical Technologies, Inc.
Cancer
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
The purpose of this study is to determine the long term tolerability and safety of dalteparin in subjects with cancer.
- Trial name
- NCT00942968
- Testing
- dalteparin
- Where
- 42 sites in United States, Austria and 3 more
- Volunteers
- 338 people
- Sponsor
- Pfizer
Macular Edema, Central Retinal Vein Occlusion
Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
The present study provided additional efficacy and safety data for 0.5-mg ranibizumab using as needed (PRN) dosing over 24 months in patients with visual impairment due to macular edema secondary to Central Retinal Vein Occlusion…
- Trial name
- CRYSTAL (NCT01535261)
- Testing
- Ranibizumab 0.5 mg/0.05 ml
- Where
- 78 sites in Australia, Austria and 16 more
- Volunteers
- 357 people
- Sponsor
- Novartis Pharmaceuticals